Companies › Transcenta Therapeutics (Hangzhou)
2 active drug programs in 3 registered trials: 3 Phase 1; Oncology, Gastroenterology; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| TST001 Anti-CLDN18.2 monoclonal antibody | CLDN18 | Phase 1 | Advanced Cancer | Jun 2027 |
| TST003 humanized anti-GREM1 monoclonal antibody | GREM1 | Phase 1 | Locally Advanced Solid Tumor | Jun 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04396821 | TST001 | Phase 1 | Advanced Cancer | Gastroenterology | Jun 2027 |
| NCT04495296 | TST001 | Phase 1 | Advanced Cancer | Oncology | Jun 2027 |
| NCT05731271 | TST003 | Phase 1 | Locally Advanced Solid Tumor | Oncology | Jun 2027 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.